Lytix Biopharma's second-quarter 2026 report was dominated by the FDA's feedback that it raises no objection to the design of a single registrational phase III trial of ruxotemitide plus pembrolizumab. The company also broadened its evidence base with ALETTA, an investigator-led phase II study testing ruxotemitide alongside ipilimumab and nivolumab. Lytix' partner Verrica's progresses toward a pivotal phase III programme for ruxotemitide (VP-315) in basal cell carcinoma, pending funding. NeoLIPA enrollment stands at 85 percent with topline data targeted for the second half of 2026. The Lytix share screens as "Fairly Valued".
LÄS MER
